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Abstract 
 This thesis presents the development of chip-based technology for informative in 
vitro cancer diagnostics. In the first part of this thesis, I will present my contribution in 
the development of a technology called “Nucleic Acid Cell Sorting (NACS)”, based on 
microarrays composed of nucleic acid encoded peptide major histocompatibility 
complexes (p/MHC), and the experimental and theoretical methods to detect and analyze 
secreted proteins from single or few cells.  
  
Secondly, a novel portable platform for imaging of cellular metabolism with radio 
probes is presented. A microfluidic chip, so called “Radiopharmaceutical Imaging Chip” 
(RIMChip), combined with a beta-particle imaging camera, is developed to visualize the 
uptake of radio probes in a small number of cells. Due to its sophisticated design, 
RIMChip allows robust and user-friendly execution of sensitive and quantitative radio 
assays. The performance of this platform is validated with adherent and suspension 
cancer cell lines. This platform is then applied to study the metabolic response of cancer 
cells under the treatment of drugs. Both cases of mouse lymphoma and human 
glioblastoma cell lines, the metabolic responses to the drug exposures are observed 
within a short time (~ 1 hour), and are correlated with the arrest of cell-cycle, or with 
changes in receptor tyrosine kinase signaling.   
  
The last parts of this thesis present summaries of ongoing projects: development 
of a new agent as an in vivo imaging probe for c-MET, and quantitative monitoring of 
glycolytic metabolism of primary glioblastoma cells. To develop a new agent for c-MET 
 vii 
imaging, the one-bead-one-compound combinatorial library method is used, coupled 
with iterative screening. The performance of the agent is quantitatively validated with 
cell-based fluorescent assays. In the case of monitoring the metabolism of primary 
glioblastoma cell, by RIMChip, cells were sorting according to their expression levels of 
oncoprotein, or were treated with different kinds of drugs to study the metabolic 
heterogeneity of cancer cells or metabolic response of glioblastoma cells to drug 
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